东曜药业-B2023年年报

277 683 1484 3086 3687 5688 執行董事 授權代表 非執行董事 股份過戶登記處 20231120238122023812 1617 註冊辦事處 獨立非執行董事 3485 中國總部及主要營業地點 審計與關聯方交易審核委員會 120 20238122023812 公司網址www.totbiopharm.com.cn 薪酬委員會 上市地點及股份代號1875 20238122023812 主要往來銀行 提名委員會 戰略及ESG委員會 20238122023812 核數師 法律顧問 • 聯席公司秘書 投資者及媒體關係顧問 2023CDMOXDCADCAXCADCADCNMPA7QPMNC2020CDMOADCADC CDMO •780,62977% 20231231 •630,207107%®CDMO/CMO140,89894%2023202254,1512023101% 20232024 2023 CDMO3944%95ADC30ADC65ADC65%6pre-BLA4CDMO •56,431(EBITDA)40,041274% •37,757202250,04612,28925% 2023ADCCDMO 2023CDMO ADCCDMODNAINDBLACDMOADCDisacLinkTMADC CDMOCMCpre-BLA 2023454302,000ADC960530ADC20236103pre-BLACDMOADC CDMOCDMO202120231019 2.5CDMOCDMO 2023 CDMOCDMO202234%84%4641215CDMO95% 20236.3CDMO ®231320242022TAB01420239TAB014CDMO 展望 2023CDMOADC CDMO 劉軍博士 2024315 財務概要 EBITDAEBITDA EBITDAEBITDAEBITDA 20238,162202233,93525,7732023EBITDA40,0412022EBITDA10,706CDMO 2023780,6292022442,178338,45177%202337,757202250,04612,28925%2023103,8902022151,168202368,310202262,5872023441,0192022203,954 CDMO/CMO 2023630,2072022304,361325,846® 2023CDMO/CMO140,898202272,53868,360CDMO/CMO CDMO 2023103,8902022151,16847,278ADC CDMO 2023441,0192022203,954237,065 202368,310202262,5875,723 202311,481202259710,884 202317,65420228,6159,039 20232,97420222,265709 20235,17520226,6021,427 202337,757202250,04612,289 20231231686,6862022715,43928,753 202312 31351,6002022417,76966,169 202356,431202259,9293,4982022164,1052022282,764118,65938,2252022481,240443,01520222023 202312 31344,285202212 31287,633265,715202212 31237,36728 (1)(2)(3) 20222023202212310.4202312310.5 202111 91.82021123183,500202112312023123170,949140,932 2021ADC20231231246,743 20231231 20231231 20231231 20231231 2023123155120231231 2023174,4632022137,960 20231231202220231231 薪酬範圍 0500,000500,0011,000,0001,000,0011,500,0001,500,0012,000,0002,000,0012,500,0002,500,0013,000,000 一、業務回顧 20231231 20232020CDMOCDMOADC CDMOADCCMCCDMOCDMOCDMO®2024 •780,62977%630,207107%®CDMO/CMO140,89894%2023202254,1512023101%56,431(EBITDA)40,041 •37,757202250,04612,28925% CDMO3944%95ADC3063ADCCDMO65ADC65%ADC(RDC)4pre-BLA6pre-BLACDMO 二、抗體偶聯藥物(ADC)迎來高速發展黃金期 1. 20214,10020257,10214.7%2030ADC202310ADCADC 2.ADC/XDC –ADC ADCADCDS-8201HER2ADC30.0%2022792030647 ADCADC1000ADC15300ADC CDMOADC(XDC)(XDC)XRDCXDC –ADC CDMOADC ADCCMCADCCDMO70%34% ADC CDMO2022152018202234.5%21.8%2030ADC CDMO1102022203028.4%ADCADC CDMO •ADCADC 三、東曜藥業CDMO業務發展及競爭優勢 1.CDMO 2023CDMOCDMO20231231CDMO/CMO140,89894%65ADC65%ADC •ADC •CDMOADCCDMOADCIND 3930ADC34IND6pre-BLA4ADC3 •(RDC) 2.ADC CDMO •ADCCDMO 2023 3.CDMO –3.2 ADCCDMO20237DisacLink™ADCDisacLink™DisacLink™DisacLink™CDMOADCDisacLink™ADC –3.1•ADC ADC•ADCCDMOADC6ADC –3.3 –3.4 ADCADCADC5kg454302000ADC960530ADC20236103pre-BLACDMOADC CDMO NMPA7QPMNC 3.5 CDMO –3.6 – CDMOpre-BLA CDMO15CDMO20231231CDMO34%46484%12CDMO95% 四、已上市產品及研發管線 1. 2023 20223TAB014(wAMD)TAB014(MAH)202310TAB0142023916TAB014 20232023115%2023123123132024 ® ®202120231231®Avastin®1002030490202120307.6%2030184202120308.3%®2022® ® ®20215 31NMPA2021®2022202312 31 •20236ADC40(2*20m2)2R-50R 五、業內領先的大規模、靈活生產能力 1. CDMO2023 •20234200L500L 2,000L •202396152R-50R100% •20236GMPADCOEB-5ADC100L, 200L, 500L5kg 六、產業交流及品牌宣傳 2023CDMOADC/XDC/AXCCDMOCDMO •20235ADCADCADC •20231025000CDMOCDMO •202392023ADCADCADCCDMO•& ADCADC •2023112023(SAPA-China) 八、公司獎項 CDMO •2023CDMOTOP10 •2023 •E2023ESGTOP20ESG 七、投資者關係 CDMOADC CDMO •ESG2023 十、未來展望 九、企業願景、使命、價值觀 2023CDMO2024XDC CDMOCDMOCDMO 䶅ᮜ喟䈓㘪䛘㬒ޢ᫝喑᣽ࡴ⩌প䈗䛼喑Ⴕ䂤ϧ䶋֒Ꮴ Ҭপ喟᜽❟㵹ẚ䵅ٵȠ჏ᝣԎ䈡⮱⩌➖䛘㬒ᰭҠव҉๒ѡ 201072016102005420107Bayer USLLCBayer Healthcare 非執行董事 20021219917 非執行董事 付山先生5620161192018928ESG 201310(VivoCapital LLC)2008620131020216229120187Sinovac Biotech Ltd.SVA2021620243Genetron Holdings LimitedGTH20182202339969688428 執行董事 劉軍博士562016101720181026201931220201015ESG201610 17202010 15202042120201015 1991719887 劉衛東博士552023812ESG 非執行董事 黃純瑩女士6520107520201015ESG20107520201015202311 CMC20011020155ArrayBioPharma Inc.ARRY(PfizerInc.)PFE2015620162Avista Pharma SolutionsCambrex CorporationCBM20163201742359603259 19864201512201141983719858 20178(Vivo Capital LLC)20191120216(Genetron Holdings Limited)GTH 1982619836 198919942000 200582005720117200910665220156649620134415720187649920206683820235173120076201964152 獨立非執行董事 胡蘭女士522019312 2020087201862002719947202039969688428 20012200411 200521994719973 198261984619876 張鴻仁先生67201931215 汪德潛博士732022312ESG 19771987199119942016(Bayer AG)BAYN201620212269 潘志衛博士5020233CMCCMC 高級管理人員 陰麗女士59202311ADC30 201912023318776881802014201815130005132012201420072012Shire HGT(Takeda) 2014920231022692268(Sigma Aldrich)(DuPont-MerckPharmaceuticals)(Amgen) 199520002007 李鴻陽先生6020241(MS&T) 201211202311Novartis AGNVSMS&T(Novo Nordisk)(Eli Lilly) 198619892003 段清博士412019420174201932011920173 高級管理人員 肖賁女士4320221202210 2021620211020161120215(Fuba Automotive Electronics GmbH)2019820051120169(Wincor Nixdorf Internation